Fatal COVID-19 Outcomes Are Associated with an Antibody Response Targeting Epitopes Shared with Endemic Coronaviruses

The role of immune responses to previously seen endemic coronavirus epitopes in severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and disease progression has not yet been determined. Here, we show that a key characteristic of fatal outcomes with coronavirus disease 2019 (COVID-19) is that the immune response to the SARS-CoV-2 spike protein is enriched for antibodies directed against epitopes shared with endemic beta-coronaviruses and has a lower proportion of antibodies targeting the more protective variable regions of the spike. The magnitude of antibody responses to the SARS-CoV-2 full-length spike protein, its domains and subunits, and the SARS-CoV-2 nucleocapsid also correlated strongly with responses to the endemic beta-coronavirus spike proteins in individuals admitted to an intensive care unit (ICU) with fatal COVID-19 outcomes, but not in individuals with nonfatal outcomes. This correlation was found to be due to the antibody response directed at the S2 subunit of the SARS-CoV-2 spike protein, which has the highest degree of conservation between the beta-coronavirus spike proteins. Intriguingly, antibody responses to the less cross-reactive SARS-CoV-2 nucleocapsid were not significantly different in individuals who were admitted to an ICU with fatal and nonfatal outcomes, suggesting an antibody profile in individuals with fatal outcomes consistent with an "original antigenic sin" type response.

Citing Articles

HCoV-NL63 and HCoV-HKU1 seroprevalence and its relationship with the clinical features of COVID-19 patients from Villavicencio, Colombia.

Lesmes-Rodriguez L, Pedraza-Castillo L, Jaramillo-Hernandez D Biomedica. 2024; 44(3):340-354.

PMID: 39241243 PMC: 11500678. DOI: 10.7705/biomedica.7168.

EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation.

Cooper R, Sutherland C, Smith L, Cowan G, Barnett M, Mitchell D Front Immunol. 2024; 15:1412211.

PMID: 39011042 PMC: 11246990. DOI: 10.3389/fimmu.2024.1412211.

Multivalent and Sequential Heterologous Spike Protein Vaccinations Effectively Induce Protective Humoral Immunity against SARS-CoV-2 Variants.

Liu R, Natekar J, Kim K, Pathak H, Bhatnagar N, Raha J Vaccines (Basel). 2024; 12(4.

PMID: 38675744 PMC: 11053539. DOI: 10.3390/vaccines12040362.

Darwin review: the evolution of virulence in human pathogens.

Gupta S Proc Biol Sci. 2024; 291(2016):20232043.

PMID: 38320607 PMC: 10846939. DOI: 10.1098/rspb.2023.2043.

Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls.

Karaba A, Morgenlander W, Johnston T, Hage C, Pekosz A, Durand C J Infect Dis. 2023; 229(5):1366-1371.

PMID: 38019656 PMC: 11095532. DOI: 10.1093/infdis/jiad534.

References

Amanat F, Thapa M, Lei T, Ahmed S, Adelsberg D, Carreno J . SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021; 184(15):3936-3948.e10. PMC: 8185186. DOI: 10.1016/j.cell.2021.06.005. View

Atyeo C, Fischinger S, Zohar T, Slein M, Burke J, Loos C . Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity. 2020; 53(3):524-532.e4. PMC: 7392190. DOI: 10.1016/j.immuni.2020.07.020. View

Aguilar-Bretones M, Westerhuis B, Raadsen M, de Bruin E, Chandler F, Okba N . Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. J Clin Invest. 2021; 131(21). PMC: 8553556. DOI: 10.1172/JCI150613. View

Dunning J, Merson L, Rohde G, Gao Z, Semple M, Tran D . Open source clinical science for emerging infections. Lancet Infect Dis. 2013; 14(1):8-9. PMC: 7158987. DOI: 10.1016/S1473-3099(13)70327-X. View

Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez S, Dan J . Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020; 370(6512):89-94. PMC: 7574914. DOI: 10.1126/science.abd3871. View

Liu Y, Soh W, Kishikawa J, Hirose M, Nakayama E, Li S . An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021; 184(13):3452-3466.e18. PMC: 8142859. DOI: 10.1016/j.cell.2021.05.032. View

Harvala H, Robb M, Watkins N, Ijaz S, Dicks S, Patel M . Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med. 2020; 31(3):167-175. PMC: 8246874. DOI: 10.1111/tme.12746. View

Anderson E, Goodwin E, Verma A, Arevalo C, Bolton M, Weirick M . Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell. 2021; 184(7):1858-1864.e10. PMC: 7871851. DOI: 10.1016/j.cell.2021.02.010. View

Mongkolsapaya J, Dejnirattisai W, Xu X, Vasanawathana S, Tangthawornchaikul N, Chairunsri A . Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003; 9(7):921-7. DOI: 10.1038/nm887. View

10.

Lumley S, Eyre D, McNaughton A, Howarth A, Hoosdally S, Hatch S . SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. Euro Surveill. 2020; 25(42). PMC: 7651878. DOI: 10.2807/1560-7917.ES.2020.25.41.2001721. View

11.

Piccoli L, Park Y, Tortorici M, Czudnochowski N, Walls A, Beltramello M . Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020; 183(4):1024-1042.e21. PMC: 7494283. DOI: 10.1016/j.cell.2020.09.037. View

12.

Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E . COVID-19, SARS and MERS: are they closely related?. Clin Microbiol Infect. 2020; 26(6):729-734. PMC: 7176926. DOI: 10.1016/j.cmi.2020.03.026. View

13.

Youngs J, Provine N, Lim N, Sharpe H, Amini A, Chen Y . Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathog. 2021; 17(9):e1009804. PMC: 8445447. DOI: 10.1371/journal.ppat.1009804. View

14.

Kumar S, Stecher G, Li M, Knyaz C, Tamura K . MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018; 35(6):1547-1549. PMC: 5967553. DOI: 10.1093/molbev/msy096. View

15.

Swadling L, Diniz M, Schmidt N, Amin O, Chandran A, Shaw E . Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2021; 601(7891):110-117. PMC: 8732273. DOI: 10.1038/s41586-021-04186-8. View

16.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

17.

Lapp S, Edara V, Lu A, Lai L, Hussaini L, Chahroudi A . Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection. PLoS One. 2021; 16(8):e0256482. PMC: 8396729. DOI: 10.1371/journal.pone.0256482. View

18.

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

19.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

20.

Wellens J, Edmans M, Obolski U, McGregor C, Simmonds P, Turner M . Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut. 2021; 71(9):1919-1922. DOI: 10.1136/gutjnl-2021-326312. View